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Introduction
The preceding paper in this series (Herbert 2000)
considered how reports of clinical trials can be used
to obtain unbiased estimates of the size of a
treatment’s effects. That paper discussed how readers
of clinical trials can extract simple estimates of
treatment effect size when trial outcomes are
measured on a continuous scale. The approach
incorporates clinical intuition and patient preferences
into clinical decision-making. It was suggested that,
when making decisions about therapy for individual
patients, optimal decision-making involves modifying
effect size estimates on the basis of patient
characteristics and comparing such estimates with the
“smallest clinically worthwhile effect”. In this paper,
the same process is applied to clinical trials in which
outcomes are measured on a dichotomous scale.
Dichotomous outcomes The examples in the
preceding paper were of clinical trials in which
outcomes were measured as continuous variables.
Continuous variables are those that can take on any of
an infinite number of values between their upper and
lower extremes. Oedema, self-reported pain on a VAS
scale and lung function tests are all examples of
continuous variables.
Other outcomes are measured as “dichotomous”
variables. Dichotomous outcomes are discrete events
- things that either happen or do not - such as death,
injury, or “satisfied with treatment”. We quantify
these outcomes of therapy in terms of the proportion
of subjects who experienced the event of interest,
usually within some specified period of time. This
tells us about the risk of the event for individuals from
that population. A good example is provided by a
recent trial of the effects of prophylactic chest
physiotherapy on respiratory complications following
major abdominal surgery (Olsen et al 1997). In this
study, the event of interest was the development of a
respiratory complication. Fifty-two of 192 subjects in
the control group experienced respiratory
complications within six days of surgery, so the risk
of respiratory complications for these subjects was
0.27 (or 27%).
In clinical trials with dichotomous outcomes, we are
interested in whether treatment reduces the risk of the
event of interest. Thus we need to determine if the risk
differs between treatment and control groups. The
magnitude of the risk reduction, which tells us about
the degree of effectiveness of the treatment, can be
expressed in a number of different ways (Guyatt et al
1994, Sackett et al 1998). Three common measures
are the absolute risk reduction, number needed to
treat and relative risk reduction.
Absolute risk reduction The absolute risk reduction
is simply the difference in risk between treatment and
control groups. In the trial by Olsen et al, a relatively
small proportion of subjects in the treatment group
(10/172 = 0.06 or 6%) experienced respiratory
complications, so the risk of respiratory
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complications for subjects in the group was relatively
small compared with the 27% risk in the control
group. The absolute reduction in risk is 0.27-0.06 =
0.21, or 21%. This means that treated subjects were at
a 21% lower risk than control group subjects of
experiencing respiratory complications in the six days
following surgery. Big absolute risk reductions
indicate treatment is very effective. Negative absolute
risk reductions indicate that risk is greater in the
treatment group than in the control group and that the
treatment is harmful. (An exception to this rule is
when the event is a positive event, such as return to
work, rather than a negative event).
Number needed to treat Understandably, many
people have difficulty in appreciating the magnitude
of absolute risk reductions. A consequence is that it is
often difficult to specify the smallest clinically
worthwhile effect in terms of absolute risk reduction
(especially when the absolute risk reduction is small).
How big is a 21% reduction in absolute risk? Is a 21%
absolute risk reduction clinically worthwhile? A
second measure of risk reduction, the number needed
to treat, makes the magnitude of an absolute risk
reduction more explicit. The number needed to treat
(NNT) is obtained by taking the inverse of the
absolute risk reduction. In our example, the absolute
risk reduction is 0.21, so the NNT is 1/0.21, or ~ 5.
This is the number of people who would need to be
treated, on average, to prevent the event of interest
once. In our example, one respiratory complication is
prevented for every five people given the treatment.
For the other four out of every five patients, the
treatment made no difference; some would not have
developed a respiratory complication anyhow, and the
others developed a respiratory complication despite
treatment. A small NNT (such as five) is better than a
large NNT (such as 100) because it indicates that a
relatively small number of patients need to be treated
before the treatment makes a difference to one of
them.
The NNT is very useful because it makes it relatively
easy to specify a smallest clinically worthwhile effect.
With the NNT, we can more easily weigh up the
benefits of preventing the event in one subject against
the costs and risks of giving the therapy (particularly
the costs and risks to the subjects on whom the
treatment had no effect). In our example, most would
agree that an NNT of 10 would be worthwhile,
because preventing one respiratory complication is a
very desirable thing, and the risks and costs of this
simple intervention are minimal, so little is lost from
ineffectively treating nine out of every 10 patients.
Most would agree, however, that an NNT of 100
would be too large to make the intervention
worthwhile. There may be little risk associated with
this intervention but it probably is too great a cost to
ineffectively treat 99 people to make the prevention of
one respiratory complication worthwhile. What, then,
is the largest NNT for prophylactic chest
physiotherapy that we would accept as being
clinically worthwhile (ie what is the smallest
clinically worthwhile effect)? When the author polled
some experienced cardiopulmonary therapists they
indicated that they would not be prepared to instigate
this therapy if they had to treat more than about 20
patients to prevent one respiratory complication. That
is, they nominated an NNT of 20 as the smallest
clinically worthwhile effect. This corresponds to an
absolute risk reduction of 5%. It would be interesting
to survey patients facing major abdominal surgery to
determine what they considered to be the smallest
clinically worthwhile effect. The size of the treatment
effect demonstrated in the trial by Olsen et al (NNT =
5) is much greater than most therapists would
consider to be minimally clinically worthwhile (NNT
~ 20; remember that a small NNT indicates large
treatment effects).
Clearly there is no one value for the NNT that can be
deemed to be the smallest clinically worthwhile
effect. The size of the smallest clinically worthwhile
effect will depend on the seriousness of the event and
the costs and risks of treatment. Thus the smallest
clinically worthwhile effect for a three-month
exercise program may be as little as two or three if the
event being prevented is infrequent giving way of the
knee, whereas the smallest clinically worthwhile
effect for the use of incentive spirometry in the
immediate post-operative period after chest surgery
may be an NNT of 100 if the event being prevented is
death. When therapy is ongoing, the NNT, like the
absolute risk reduction, should be related to the
period of therapy. An NNT of 10 for a three-month
course of therapy aimed at reducing respiratory
complications in children with cystic fibrosis  is
similar in the size of its effect to another therapy
which has an NNT of five for a six-month course of
therapy.
Relative risk reduction A more common but less
immediately helpful way of expressing the reduction
in risk is as a proportion of the risk of untreated
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patients. This is termed the relative risk reduction.
The relative risk reduction is obtained by dividing the
absolute risk reduction by the risk in the control
group. Thus the relative risk reduction produced by
prophylactic chest physiotherapy is 0.21/0.27, which
is 0.78 or 78%. In other words, prophylactic chest
physiotherapy reduced the risk of repiratory
complications by 78% of the risk of untreated
patients. It can be seen that the relative risk reduction
(78%) is much larger than the absolute risk reduction
(21%). In fact, the relative risk reduction is always
larger than the absolute risk reduction, because it is
obtained by dividing the absolute risk reduction by a
number which is always less than 1. Which, then, is
the best measure of the magnitude of a treatment’s
effects? Should we use the absolute risk reduction, its
inverse (the NNT), or the relative risk reduction?
The relative risk reduction has some properties that
make it useful for comparing the findings of different
studies, but it can be deceptive when used for clinical
decision-making. For example, Lauritzen et al (1993)
showed that the provision of hip protector pads to
residents of nursing homes produced large relative
reductions in risk of hip fracture (relative risk
reduction of 56%). This might sound like the
treatment has a big effect, and it may be tempting to
conclude, on the basis of this statistic, that the hip
protectors are clinically worthwhile. However, the
incidence of hip fractures in a nursing home
population is about 5% per year (Lauritzen et al
1993), so the absolute reduction of hip fracture risk
with hip protectors in this population is 56% of 5%,
or less than 3%. By converting this to an NNT, it can
be seen that 36 people would need to wear hip
protectors for one year to prevent one fracture. When
the risk reduction is expressed as an absolute risk
reduction or, better still as an NNT, the effects appear
small, and may be too small to be clinically
worthwhile. This example illustrates that it is
probably better to make decisions about the
magnitude of treatment effects in terms of absolute
risk reductions or numbers needed to treat than
relative risk reductions.
The importance of baseline risk In general, even the
best treatments (those with large relative risk
reductions) will produce only small absolute risk
reductions when the risk of the event in untreated
subjects (the “baseline risk”) is low. Perhaps this is
intuitively obvious - if few people are likely to
experience the event, it is not possible to prevent it
very often. There are two very practical implications.
First, even the best treatments are unlikely to produce
clinically worthwhile effects if the event that is to be
prevented is unlikely. The converse of this is that a
treatment is more likely to be clinically worthwhile
when it reduces risk of a high risk event. (For a
particularly clear discussion of this issue see Glasziou
and Irwig 1995.) Second, as the magnitude of the
treatment effect is likely to depend very much on the
risk that untreated subjects are exposed to, care is
needed when applying the results of a clinical trial to
a particular patient if the risk to patients in the trial
differs markedly from the risk in the patient for whom
the treatment is being considered. If the risk in control
subjects in the trial is much higher than in the patient
in question, the size of the treatment effect will tend
to be overestimated (that is, the absolute risk
reduction calculated from trial data will be too high,
and the NNT will be too low).
There is a simple work-around that makes it possible
to apply the results of a clinical trial to patients with
higher or lower levels of risk. The approach described
here is based on the method used by Straus and
Sackett (1999; see also McAlister et al 2000). The
absolute risk reduction or NNT is calculated as
described above directly from the results of the trial,
but is then adjusted by a factor, f, which describes
how much more at risk subjects are, than the
untreated (control) subjects in the trial. An f of greater
than 1 is used when the patients to whom the result is
to be applied are at a greater risk than control subjects
in the trial, and an f of less than 1 is used when
patients to whom the result is to be applied are at a
lower risk than untreated subjects in the trial. The
absolute risk reduction is adjusted by multiplying by f
and the NNT is adjusted by dividing by f.
The following example illustrates how this approach
might be used. A therapist treating a morbidly obese
patient undergoing major abdominal surgery might
estimate that the patient was at twice the risk of
respiratory complications as subjects in the trial by
Olsen et al (1997). To obtain a reasonable estimate of
the effects of therapy (that is, to take into account the
greater baseline risk in this subject than in subjects in
the trial) the NNT (which we previously calculated as
5) could be divided by 2. This gives an NNT of 2.5
(which rounds to 3) for morbidly obese subjects. Thus
we can anticipate an even larger effect of prophylactic
physiotherapy amongst high-risk patients. This
approach can be used to adjust estimates of the likely
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effects of treatment for any individual patient up or
down on the basis of therapists’ perceptions of that
patient’s risk.
Calculating confidence intervals for treatment
effects on dichotomous outcomes As with trials that
measure continuous outcomes, many trials with
dichotomous outcomes do not report confidence
intervals about the relative risk reduction, absolute
risk reduction or NNT. Most do, however, supply
sufficient data to calculate the confidence interval. A
rough 95% confidence interval for the absolute risk
reduction can be obtained simply from the average
sample size (n) of the experimental and control
groups:
95% CI = difference in risk ± 1/√n
(for the derivation of this equation, see the Appendix).
This approximation works quite well (it gives an
answer that is quite close to that provided by more
complex equations) when the average risk of the
events of interest in treated and control groups is
greater than ~ 10% and less than ~ 90%.
To illustrate the calculation of confidence intervals
for dichotomous data, recall that in the study by Olsen
et al (1997)  the risk to control subjects was 0.27, the
risk to experimental subjects was 0.06, and the
average size of each group was 182, so:
95% CI = 0.27 - 0.06 ± 1/√182
95% CI = 0.21 ± 0.07
Thus the best estimate of the absolute risk reduction
is 21% and its 95% confidence interval extends from
14% to 28%. Inverting the 95% confidence interval of
the absolute risk reduction gives a 95% confidence
interval for the NNT that extends from 4 to 7.
This result has been illustrated on a tree graph of the
absolute risk reduction in Figure 1. The logic of this
tree graph is exactly the same as that used for the tree
graph of a continuous variable which was presented in
the preceding paper (Herbert 2000) except that, by
convention, a positive effect (a risk reduction) is to
the left. Again we plot the smallest clinically
worthwhile effect (absolute risk reduction of 5%,
corresponding to an NNT of 20), the treatment effect
size (absolute risk reduction of 21%) and its
confidence interval (14% to 28%) on the graph. In
this example, the estimated absolute risk reduction
and its confidence interval are clearly greater than the
smallest clinically worthwhile effect, so we can
confidently conclude that this treatment is clinically
worthwhile. For morbidly obese patients (for whom
we could multiply the absolute risk reduction by an f
of 2 to take into account their greater untreated risk),
the therapy is even more worthwhile.
This paper and the preceding paper in this two-part
series have described a process which can be used to
incorporate information from clinical trials in clinical
decision-making. Good clinical trials provide
reasonably unbiased estimates of the size of treatment
effects. These estimates can be modified on the basis
of patient characteristics and then compared with the
smallest clinically worthwhile effect to determine if
the therapy is likely to do more good than harm.
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Appendix.
Approximate 95% confidence intervals for absolute risk reduction.
The usual equation for the confidence interval about the absolute risk reduction (ie the difference between two
proportions) is:
95% CI = difference in risk ± z
(1-α/2) 
x
where z
(1-a/2)
is the appropriate value from a z-distribution, R
c
is the risk to subjects in the control group, R
t
is the
risk to subjects in the treatment group, and n
c
and n
t
are the number of subjects in control and treatment groups
respectively (Gardner and Altman, 1989). Under some conditions, particularly when R
c
and R
t
are near 0 or 100%
and n is small, this equation is not very accurate (Newcombe 1998, 1999), but for most clinical purposes it is
sufficient. In randomised clinical trials the group sizes are usually similar (i.e. n
t
≈ n
c
), so we can replace n
t
and
n
c
with n
av
, the average size of the two groups. Also, z
(1-a/2)
≈ 2, so this expression simplifies to
95% CI = difference in risk ± 2 x
x Piantadosi (1997) has pointed out that R[1-R] varies relatively little with R, at least over the range of 0.1 < R
< 0.9. To simplify the equation, we can assign a value of 1 to the term 
2 x √(R
c
[1-R
c
] + R
t
[1-R
t
]), and the equation reduces to:
95% CI = difference in risk ± 1/√n
Analysis of the errors associated with this approximation is complex, but the approximation appears to work
reasonably well. Even with small sample sizes (eg n = 30), the relative error (error as a proportion of the width
of the “true” confidence interval) is typically less than 20%, which is probably sufficient for clinical decision
making.
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